This is the first study that has successfully selected and used an scFv biomarker for the diagnosis of human strongyloidiasis, which was applied in the detection of immune complexes in serum samples of patients with great accuracy, aiming the newly found HSP60 as the target antigen. This evidence concerns the gene HSPD1 and strongyloidiasis.